Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanoform FinlandFRA:4YL -4.55%63 PS Ratio is 16.43 as of Jul. 15, 2026, which is 74% below its 10-year median of 64.14. GuruFocus rates FRA:4YL with a GF Score™ of 63/100 and a GF Value™ of €1.72 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 930 Biotechnology companies, Nanoform Finland ranks worse than 62.37% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Nanoform Finland's share price is €0.756.
Nanoform Finland's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.05. Hence, Nanoform Finland's PS Ratio for today is 16.43.
The historical rank and industry rank for Nanoform Finland's PS Ratio or its related term are showing as below:
FRA:4YL'
s PS Ratio Range Over the Past 10 Years
Min: 9.13 Med: 64.14 Max: 1500
Current: 15.87
During the past 10 years, Nanoform Finland's highest PS Ratio was 1500.00. The lowest was 9.13. And the median was 64.14.
FRA:4YL's PS Ratio is ranked worse than 62.37% of 930
companies
in the Biotechnology industry
Industry Median: 9.695
vs FRA:4YL: 15.87
Nanoform Finland PLC revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Nanoform Finland was 35.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -3.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 19.50% per year.
During the past 10 years, Nanoform Finland's highest 3-Year average Revenue per Share Growth Rate was 255.70% per year. The lowest was -3.10% per year. And the median was 54.60% per year.
Back to Basics: PS Ratio
Nanoform Finland (FRA:4YL) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Nanoform Finland PS Ratio Related Terms
Nanoform Finland PS Ratio Historical Data
* Premium members only.
The historical data trend for Nanoform Finland's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nanoform Finland's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanoform Finland PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanoform Finland's PS Ratio distribution charts can be found below:
* The bar in red indicates where Nanoform Finland's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Nanoform Finland's Share Price of today is €0.756. Nanoform Finland's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.05.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Nanoform Finland (FRA:4YL) has a PS Ratio of 16.43 as of Jul. 15, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Nanoform Finland and its competitors. This is 74% below median its historical median of 64.14. Over the past decade, Nanoform Finland's PS Ratio has ranged from 9.13 to 1,500.00. According to the industry distribution chart, Nanoform Finland ranks #580 out of 930 companies in the Biotechnology industry, placing it in the top 62.4%.
Is Nanoform Finland's PS Ratio too high?
Nanoform Finland's current PS Ratio of 16.43 is 74% below median its 10-year median of 64.14. Over the past 10 years, this metric has ranged from a low of 9.13 to a high of 1,500.00. The Biotechnology industry median PS Ratio is 9.70. Nanoform Finland's value of 16.43 is 69.5% above this industry median. Based on the distribution chart, Nanoform Finland ranks #580 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nanoform Finland has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanoform Finland's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanoform Finland ranks #580 out of 930 companies for PS Ratio. This places Nanoform Finland in the lower half of its industry. The industry median PS Ratio is 9.70. Nanoform Finland's value of 16.43 is 69.5% above this benchmark. Historically, Nanoform Finland's own PS Ratio has ranged from 9.13 to 1,500.00 over the past decade. While the company's 10-year median is 64.14 vs. the industry median of 9.70, Nanoform Finland has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.70, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanoform Finland's current PS Ratio of 16.43 is 69.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Nanoform Finland and its competitors. For the Biotechnology industry, the median PS Ratio is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanoform Finland's current PS Ratio is 16.43, which is 74% below median its own 10-year median of 64.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanoform Finland stock overvalued right now?
Based on GuruFocus' analysis, Nanoform Finland (FRA:4YL) is currently considered Possible Value Trap. The stock's GF Value™ is €1.72, compared to a current price of €0.76 — trading 56% below its estimated fair value. The current PS Ratio is 16.43, which is 74% below median its 10-year median of 64.14 and 69.5% above the Biotechnology industry median of 9.70. Nanoform Finland's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Nanoform Finland (FRA:4YL), the current PS Ratio is 16.43 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanoform Finland (FRA:4YL) Overvalued in 2026?
Based on GuruFocus' analysis, Nanoform Finland stock appears to be undervalued.
The current stock price of €0.76 is trading 56% below its estimated GF Value™ of €1.72.
GuruFocus considers Nanoform Finland to be Possible Value Trap.
Key valuation signals for FRA:4YL:
PS Ratio: 16.43 (74% below median its 10-year median of 64.14)
GF Value™: €1.72 vs. price of €0.76 (56% below fair value)
Industry Position: 69.5% above the Biotechnology median (#580 of 930)
No single metric tells the full story. See the FRA:4YL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications. Geographically, the company generates maximum revenue from Europe, followed by the United States and other regions.
63GF Score
Get the complete analysis for FRA:4YL
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4YL has been successfully added to your 
